Dr Steven R Goldstein MD is a menopause specialist in NYC. He was awarded the Thomas A Clarkson award for his many outstanding contributions to menopause related clinical or basic science research and is a Past President of both The Menopause Society and the International Menopause Society. He is a Certified Menopause Practitioner.
Menopause marks a significant transition in a woman’s life, often accompanied by a range of physical and emotional changes. Among these, the decline in estrogen production is a defining biological event. This hormonal shift leads to a variety of physiological changes, one of the most impactful being vaginal atrophy. Despite its prevalence and the significant effect it can have on quality of life, vaginal atrophy remains a largely under-discussed condition, with many women unaware that effective, safe treatments exist.
When estrogen production ceases during menopause, the vaginal tissues undergo substantial alterations. The vagina becomes atrophic—it loses its blood supply and elasticity, and its natural pH balance is disrupted. These changes result in a thinning and drying of the vaginal walls, leading to symptoms such as discomfort, itching, and most notably, painful intercourse.
This condition, known clinically as genitourinary syndrome of menopause (GSM), is not merely a natural consequence of aging but a medical condition with clear underlying causes and viable treatment options.
Unfortunately, societal stigma and lack of education contribute to a widespread silence surrounding these symptoms. Recent studies have revealed that up to 50% of postmenopausal women are unaware that treatments for vaginal atrophy are available and safe. Many women mistakenly accept these symptoms as an inevitable part of aging. As a result, they suffer in silence, often experiencing a diminished quality of life and strain in intimate relationships. The misconception that nothing can be done prevents them from seeking help, and their concerns remain unaddressed.
Dr. Goldstein, a leading menopause specialist NYC, emphasizes the importance of maintaining sexual intimacy in partnered relationships. According to him, sexual health is an integral part of overall well-being, and vaginal atrophy should not be a barrier to intimacy or personal comfort. Importantly, there are several evidence-based treatment options available that can effectively manage the symptoms of vaginal atrophy, many of which have been in use for years and are well-tolerated.
Among the most commonly prescribed therapies are low-dose estrogen treatments, which come in various forms including creams, tablets, and vaginal rings. These treatments work by delivering a small amount of estrogen directly to the vaginal tissues, restoring moisture, elasticity, and normal pH levels without significantly affecting systemic hormone levels. As a result, they offer targeted relief with minimal risk, especially for women who may have concerns about hormone therapy.
In addition to traditional estrogen therapies, there are newer, non-estrogen alternatives. One such option is an oral medication that has shown promise not only in treating vaginal atrophy but also in potentially supporting bone and breast health—an important consideration for postmenopausal women. Another innovative approach involves the use of DHEA (dehydroepiandrosterone) in the form of a local vaginal insert. While DHEA is not classified as a hormone therapy, it is metabolized within the vaginal tissues to produce both estrogen and testosterone, offering symptom relief without systemic hormonal exposure.
The availability of multiple treatment options means that women can work with their healthcare providers to find a solution tailored to their individual needs and medical history. However, the first and most critical step is awareness. Healthcare professionals must take a proactive role in discussing vaginal health with menopausal patients. Likewise, public health campaigns and educational resources should strive to destigmatize this topic and empower women with information.
In conclusion, vaginal atrophy is a common but treatable condition that affects many women during and after menopause. The silence and misconceptions surrounding this issue only serve to exacerbate the suffering of those affected. By fostering open conversations, promoting awareness, and encouraging access to safe and effective treatments, we can help ensure that no woman has to endure these symptoms alone. Menopause is a natural stage of life, but living with untreated vaginal atrophy does not have to be.
Women who are experiencing vagina atrophy or painful intercourse, may schedule an appointment with Dr Goldstein a leading hormone specialist NYC .
No comments:
Post a Comment